Table 4.
Overview of patients with metastatic T1b OAC
| Case | EMR tumour histopathology | Treatment after index EMR | Time till metastases (mo)1 | Additional treatment | End study outcome | Cause of death | Survival2 (mo) |
| 1 | Sm2/3, G3, LVIX, R1 | Surgery | 4 | Chemotherapy | Deceased | OAC | 45 |
| 2 | SmX, G3, LVI+, R1 | Surgery | 2 | None | Alive | / | 87 |
| 3 | SmX, G3, LVI+, R1 | Surgery | 4 | CRT | Deceased | OAC | 8 |
| 4 | Sm2/3, G3, LVI+, R1 | Surgery | 2 | Chemotherapy | Alive | / | 55 |
| 5 | Sm2/3, G3, LVIX, R1 | Conservative | 38 | CRT | Deceased | OAC | 40 |
| 6 | Sm2/3, G2, LVI+, R1 | Conservative | 4 | CRT | Deceased | OAC | 9 |
| 7 | Sm2/3, G2, LVI-, R1 | Conservative | 3 | CRT | Deceased | OAC | 31 |
| 8 | Sm2/3, G2, LVI+, R1 | Conservative | 4 | CRT | Deceased | OAC | 18 |
| 9 | Sm1, G2, LVI-, R1 | Conservative | 17 | EMR T1a, CRT | Alive | / | 26 |
| 10 | Sm2/3, G3, LVI-, R1 | Conservative | 13 | Radiotherapy | Deceased | OAC | 30 |
1
Time from index EMR until LNM/metastatic disease;
2
Time from index EMR until the end of the study or death of the patient. EMR: Endoscopic mucosal resection; LNM: Lymph node metastases; Sm1: Submucosal invasion < 500 μm; Sm2/3: Submucosal invasion > 500 μm; G2: Moderately differentiated tumour; G3: Poorly differentiated tumour; LVI: Lymphovascular invasion; R0: Complete resection; R1: Incomplete resection; X: Indefinite; CRT: Chemoradiation therapy; OAC: Oesophageal adenocarcinoma; N/A: Not available.